Last Updated: August 8, 2026

ENBUMYST Drug Patent Profile

Name: ENBUMYST Drug Patent, Exclusivity, and Generic Launch Dataset
Creator: DrugPatentWatch
License: https://www.drugpatentwatch.com/terms.php

✉ Email this page to a colleague

« Back to Dashboard

Which patents cover Enbumyst, and when can generic versions of Enbumyst launch?

Enbumyst is a drug marketed by Corstasis Therap and is included in one NDA. There are four patents protecting this drug.

This drug has eleven patent family members in nine countries.

The generic ingredient in ENBUMYST is bumetanide. There are six drug master file entries for this compound. Forty suppliers are listed for this compound. Additional details are available on the bumetanide profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Enbumyst

A generic version of ENBUMYST was approved as bumetanide by SAGENT on January 27^th, 1995.

Start Trial

AI Deep Research

Questions you can ask:

What is the 5 year forecast for ENBUMYST?
What are the global sales for ENBUMYST?
What is Average Wholesale Price for ENBUMYST?

Summary for ENBUMYST

International Patents:	11
US Patents:	4
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
What excipients (inactive ingredients) are in ENBUMYST?	ENBUMYST excipients list
DailyMed Link:	ENBUMYST at DailyMed

Drug patent expirations by year for ENBUMYST

Pharmacology for ENBUMYST

Drug Class	Loop Diuretic
Physiological Effect	Increased Diuresis at Loop of Henle

US Patents and Regulatory Information for ENBUMYST

ENBUMYST is protected by four US patents.

+ Get email alerts for changes to this table

Glossary

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Corstasis Therap	ENBUMYST	bumetanide	SPRAY;NASAL	219500-001	Sep 12, 2025		RX	Yes	Yes	⤷ Start Trial	⤷ Start Trial	Y			⤷ Start Trial
Corstasis Therap	ENBUMYST	bumetanide	SPRAY;NASAL	219500-001	Sep 12, 2025		RX	Yes	Yes	⤷ Start Trial	⤷ Start Trial	Y			⤷ Start Trial
Corstasis Therap	ENBUMYST	bumetanide	SPRAY;NASAL	219500-001	Sep 12, 2025		RX	Yes	Yes	⤷ Start Trial	⤷ Start Trial	Y			⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

International Patents for ENBUMYST

See the table below for patents covering ENBUMYST around the world.

Subscribe to access the full database, or Start Trial
Country	Patent Number	Title	Estimated Expiration
Australia	2020397176	Methods and compositions for treating edema refractory to oral diuretics	⤷ Start Trial
Brazil	112022010879	MÉTODOS E COMPOSIÇÕES PARA TRATAMENTO DE EDEMA REFRATÁRIO A DIURÉTICOS ORAIS	⤷ Start Trial
Canada	3160278	PROCEDES ET COMPOSITIONS POUR TRAITER UN OEDEME REFRACTAIRE A DES DIURETIQUES ORAUX (METHODS AND COMPOSITIONS FOR TREATING EDEMA REFRACTORY TO ORAL DIURETICS)	⤷ Start Trial
>Country	>Patent Number	>Title	>Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.